Security key
64136E102
Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP)
CUSIP: 64136E102
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Total 13F shares
- 163,114
- Total 13F value
- $935,356
- Share change
- +83,395
- SEC-reported price per share
- $5.76
- Number of holders
- 7
- Value change
- +$529,238
- Number of buys
- 3
- Number of sells
- 4
- Shares outstanding
- 5,404,113
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
7
Top holders
7
NEUP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Neuphoria Therapeutics Inc. SEC filings
Neuphoria Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 64136E102
Recent filing periods:
Ownership snapshot
Top reported holders of NEUP - Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
9/9
Latest evidence
24 Jan 2025
13D/G
13F
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 9 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
9 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
Apeiron Investment Group Ltd.
4.5%
Lynx1 Capital Management LP
0.85%
JANE STREET GROUP, LLC
0.25%
Merck & Co., Inc.
0.19%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$5,365,401
1,033,796 shares
|
$0 | 31 Dec 2024 |
| Apeiron Investment Group Ltd. |
13D/G
|
4.5%
|
$376,887
72,618 shares
|
$0 | 24 Jan 2025 |
| Lynx1 Capital Management LP |
13F
Company
|
0.85%
|
$157,115
45,806 shares
|
— | 31 Dec 2024 |
| JANE STREET GROUP, LLC |
13F
Company
|
0.25%
|
$45,657
13,311 shares
|
— | 31 Dec 2024 |
| Merck & Co., Inc. |
13F
Company
|
0.19%
|
$34,393
10,027 shares
|
— | 31 Dec 2024 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
0.12%
|
$22,240
6,484 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
163,114
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2026 Across Filers
Q1 2026 holders
19
Q1 2025 holders
7
Holder diff
-12
| Investor | Q1 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend